Cardiovascular Risk
GLP-1 medications provide powerful cardiovascular protection, reducing major adverse cardiovascular events by 20-26% in high-risk patients.
MACE reduction
20-26%
Blood pressure reduction
5-10 mmHg
Stroke risk reduction
39%
Condition Guide
Cardiovascular Risk
Cardiovascular Benefits
GLP-1 medications reduce cardiovascular risk through multiple pathways beyond weight loss. They improve endothelial function and reduce arterial inflammation. They lower blood pressure 5-10 mmHg systolic. They improve lipid profiles, reducing triglycerides 20-30% and increasing HDL. They reduce visceral fat, which drives cardiac risk. They improve heart rate variability and reduce arterial stiffness. The SELECT trial showed semaglutide reduced MACE by 20% in patients with obesity and CVD. SUSTAIN-6 demonstrated 26% reduction in cardiovascular events with semaglutide in diabetes patients.
Who Benefits Most
Patients with established cardiovascular disease, diabetes, or multiple risk factors benefit most. Those with obesity plus hypertension, dyslipidemia, or family history of heart disease see significant risk reduction. Even patients without diabetes experience cardiovascular benefits from weight loss and metabolic improvement.
Frequently Asked Questions
Do GLP-1s prevent heart attacks?
Yes, semaglutide reduced major cardiovascular events by 20% and stroke by 39% in high-risk patients. FDA approved Wegovy for cardiovascular risk reduction.
SeraVia formulations support cardiovascular health alongside GLP-1 therapy for comprehensive risk reduction.
Learn More →Find cardiometabolic specialists
Compare pricing, reviews, and availability across 18,000+ GLP-1 providers.
Search Providers →Explore all conditions
Learn how GLP-1 medications treat different conditions — from diabetes to PCOS to cardiovascular disease.